• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Madrigal Pharmaceuticals, Inc. - Common Stock (NQ:MDGL)

    519.35 +5.63 (+1.10%)
    Streaming Delayed Price Updated: 12:14 PM EDT, May 4, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Madrigal Pharmaceuticals, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9 10 Next >
    News headline image
    MDGL Stock Alert: The Historic Reason Madrigal Is Up 19% Today ↗
    Madrigal Pharmaceuticals stock is up on Friday as MDGL investors celebrate FDA approval of NASH treatment Rezdiffra today. 
    Via InvestorPlace
    News headline image
    12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
     
    Via Benzinga
    News headline image
    Why Cardlytics Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket ↗
    Shares of Cardlytics, Inc. (NASDAQ: CDLX) rose sharply in today’s pre-market trading after the company reported better-than-expected fourth-quarter earnings. 
    Via Benzinga
    News headline image
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗
    It's time to start the final day of trading this week with a look into the biggest pre-market stock movers for Friday morning! 
    Via InvestorPlace
    News headline image
    Madrigal Pharmaceuticals: Q4 Earnings Insights ↗
     
    Via Benzinga
    News headline image
    Analyst Ratings for Madrigal Pharmaceuticals ↗
     
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Thursday's After-Market Session ↗
     
    Via Benzinga
    News headline image
    Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
    Shares of Limbach Holdings, Inc. (NASDAQ: LMB) fell sharply during Thursday’s session after the company reported fourth-quarter financial results and issued FY24 revenue guidance below estimates. 
    Via Benzinga
    News headline image
    Why Madrigal Stock, Which Has Gained 62% In A Month, Just Slumped Ahead Of A Potential First-Ever In MASH ↗
    The company hopes to be the first to the finish line with a treatment for MASH. 
    Via Investor's Business Daily
    News headline image
    2 Risky Stocks With Massive Potential ↗
    Neither is doing well this year. 
    Via The Motley Fool
    News headline image
    Missed Out on Eli Lilly? 3 Healthcare Stocks With Big Catalysts on the Horizon. ↗
    Good news could be in store for all three of these drugmakers. 
    Via The Motley Fool
    News headline image
    1 Wall Street Analyst Thinks Madrigal Pharmaceuticals Stock Is Going to $347. Is It a Buy Around $247? ↗
    This business could be on the cusp of making medical history. 
    Via The Motley Fool
    News headline image
    Biotech Stocks Madrigal, Altimmune In A Tizzy As New Weight-Loss Rival Enters The Arena ↗
    The results from Boehringer Ingelheim and Zealand Pharma bolstered some biotech stocks. But not all got the same boost. 
    Via Investor's Business Daily
    News headline image
    1 Beaten-Down Stock That Could Soar by 40%, According to Wall Street ↗
    The company might have a bright future, but is now the right time to buy shares? 
    Via The Motley Fool
    News headline image
    Analysts see over 50% gains in these 2 mid-cap biotech stocks
    The outlook for growth has made biotech one of the hottest investments of late - and Wall Street sees big comeback gains ahead in these two biotechs. 
    Via MarketBeat
    Topics Artificial Intelligence
    News headline image
    Viking Therapeutics Charges To A Record High On An Update For Its Eli Lilly-Rivaling Obesity Drug ↗
    The company is looking to take on Eli Lilly's tirzepatide as both a shot and a pill for weight loss. 
    Via Investor's Business Daily
    News headline image
    Madrigal Pharmaceuticals Stock Shows Rising Relative Strength ↗
    A Relative Strength Rating upgrade for Madrigal Pharmaceuticals shows improving technical performance. 
    Via Investor's Business Daily
    News headline image
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
     
    Via Benzinga
    News headline image
    2 Rising Biotechs That Could Become the Next Novo Nordisk ↗
    Each of these companies has a big market in its sights. 
    Via The Motley Fool
    News headline image
    2 Stocks That Could Soar This Year: Are They Buys? ↗
    They might perform well in 2024, but how will they do beyond that? 
    Via The Motley Fool
    News headline image
    Liver Disease Player 89Bio Downgraded: Analyst Sees Short-Term Uncertainties In Fatty Liver Drug Development ↗
    89Bio's journey in the clinical-stage biopharmaceutical space. RBC Capital Markets downgrades with insights on FGF21 drugs, pegozafermin, and 2024 uncertainties. 
    Via Benzinga
    News headline image
    3 Stocks That Could Be Monster Winners in 2024 ↗
    Don't be surprised if these three stocks take off in the new year. 
    Via The Motley Fool
    News headline image
    Why Comtech Telecommunications Shares Are Trading Lower By Over 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
    Shares of Comtech Telecommunications Corp. (NASDAQ: CMTL) moved lower during Friday’s session following weak quarterly earnings. 
    Via Benzinga
    News headline image
    These 2 Stocks Could Be About to Soar: Are They Buys? ↗
    One thing is for certain -- both of these companies are innovators. 
    Via The Motley Fool
    News headline image
    Got $2,000? 3 Growth Stocks to Buy That Could Double Your Money ↗
    These stocks just might have investors seeing double over the next few years. 
    Via The Motley Fool
    News headline image
    Can Weight-Loss Drug Ozempic Tip The Scales For Tema's New Healthcare ETF? ↗
    New class of weight-reducing drugs underpin launch of exchange-traded fundTema launches healthcare ETF focused on companies researching and treating cardiovascular disease, obesity and diabetes,... 
    Via Benzinga
    Topics ETFs
    News headline image
    Madrigal Pharmaceuticals Stock Clears Benchmark, Hits 80+ RS Rating ↗
    Madrigal Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 86. 
    Via Investor's Business Daily
    News headline image
    The 3 Most Undervalued Biotech Stocks to Buy: November 2023 ↗
    Given the undervalued biotech industry, these three undervalued biotech stocks to buy are ripe purchase targets for high-potential profits. 
    Via InvestorPlace
    News headline image
    10 Health Care Stocks Whale Activity In Today's Session ↗
     
    Via Benzinga
    News headline image
    10 Health Care Stocks Whale Activity In Today's Session ↗
     
    Via Benzinga
    < Previous 1 2 3 4 5 6 7 8 9 10 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.